Please login to the form below

Not currently logged in
Email:
Password:

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

Merck and Co - US headquartersMerck & Co has submitted its single-tablet combination therapy for hepatitis C virus (HCV) to the US FDA as it tries to catch up with the leading players in the all-oral therapy sector.

Merck - known as MSD outside the US - is seeking marketing approval for a once-daily fixed-dose combination of its NS3/4A protease inhibitor grazoprevir and elbasvir, an NS5A replication complex inhibitor, which has been awarded breakthrough status by the FDA.

If approved, the one-tablet, once-daily formulation will be a direct competitor to Gilead Science's Harvoni (sofosbuvir/ledipasvir), which is growing at a phenomenal rate since its launch towards the end of last year with first-quarter sales topping $3.5bn.

Merck has filed grazoprevir/elbasvir initially for the treatment of adult patients with chronic infections with HCV genotypes 1, 4 or 6, and says it will submit additional license applications in the EU and other markets by the end of the year.

While Merck is playing catch-up in the market with Harvoni and other rivals such as AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) - which achieved first-quarter sales of $231m - analysts have suggested its combination could eventually achieve sales in the region of $2bn a year.

A key factor in those predictions rests in the combination's benign profile in patients with HCV and concomitant kidney disease - in fact, the FDA's breakthrough designation was awarded specifically for the drug's use in patients with end stage renal disease who need haemodialysis as well as for those with genotype 4 HCV.

An earlier, more general breakthrough status in HCV was rescinded by the FDA after other all-oral HCV regimens reached the market.

In addition to kidney disease, Merck is also exploring the use of its drug in other hard-to-treat HCV setting - including co-infection with HIV, inherited blood disorders, liver cirrhosis and in patients receiving opiate substitution therapy to tackle addiction - that could help differentiate it from its rivals.

Meanwhile, Merck is also developing an HCV polymerase inhibitor - called MK-3682 - that it is testing alongside grazoprevir/elbasvir and other dual HCV therapies and is due to start phase III later this year.

Article by
Phil Taylor

29th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics